SCHEMBL855440

SCHEMBL855440

O=C1NC(=O)C(COC(=O)C(Cl)Cl)N1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.38
ADAMTS5 Q9UNA0 11/20 0.36
ADAM17 P78536 4/20 0.36
ADAMTS4 O75173 2/20 0.36
ADAM10 O14672 1/20 0.36
MMP12 P39900 1/20 0.36
ADAM9 Q13443 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MMP2 P08253 1/20 0.34
ALDH1A1 P00352 2/20 0.33
MEN1 O00255 1/20 0.33
CASP1 P29466 1/20 0.33
KMT2A Q03164 1/20 0.33
RGS12 O14924 1/20 0.33
TSHR P16473 1/20 0.33
LMNA P02545 1/20 0.32
HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL855469 0.78 GAA (0.37) GAAADAMTS5ADAM17ADAMTS4ADAM10
SCHEMBL18009344 0.77 GAA (0.39) GAAADAMTS5ADAM17ADAMTS4ADAM10
SCHEMBL18007465 0.77 GAA (0.39) GAAADAMTS5ADAM17ADAMTS4ADAM10
SCHEMBL18007464 0.77 GAA (0.39) GAAADAMTS5ADAM17ADAMTS4ADAM10
SCHEMBL17969458 0.73 HCAR2 (0.42) GAAADAMTS5ADAMTS4SMN1; SMN2ALDH1A1
SCHEMBL17966450 0.73 HCAR2 (0.42) GAAADAMTS5ADAMTS4SMN1; SMN2ALDH1A1
SCHEMBL18009093 0.71 HCAR2 (0.44) GAAADAMTS5ADAM17SMN1; SMN2MMP2
SCHEMBL18009125 0.71 HCAR2 (0.39) GAAADAMTS5ADAM17SMN1; SMN2ALDH1A1
SCHEMBL18009090 0.71 HCAR2 (0.39) GAAADAMTS5ADAM17SMN1; SMN2ALDH1A1
SCHEMBL18009089 0.71 HCAR2 (0.47) SMN1; SMN2ALDH1A1MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420683-B2 5 substituted hydantoins DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) 2013-04-16 US disclosed
EP-2150538-B1 NOVEL 5-SUBSTITUTED HYDANTOINS DSM SINOCHEM PHARM NL BV (NL) 2012-03-28 EP disclosed
US-20100174092-A1 NOVEL 5 SUBSTITUTED HYDANTOINS DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) 2010-07-08 US disclosed
EP-2150538-A2 NOVEL 5-SUBSTITUTED HYDANTOINS DSM IP Assets B.V. (NL) 2010-02-10 EP disclosed
WO-2008148755-A2 NOVEL 5-SUBSTITUTED HYDANTOINS DSM IP ASSETS B.V. (NL) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100174092-A1 NOVEL 5 SUBSTITUTED HYDANTOINS CYP3A5, REN, ACE GAA 2157/4885ADAMTS5 1271/4885ADAM17 575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.